Two mood-stabilizing drugs provide protection against a potentially dangerous virus implicated in birth defects as well as disease in people with compromised immune systems, Yale School of Medicine researchers have found.
The related drugs, valnoctamide and valpromide, are approved for treatment of neurologic and psychiatric brain disorders such as epilepsy and bipolar disorder; both inhibit cytomegalovirus (CMV), one of the major causes of birth defects in infected fetuses, the researchers report Sept. 21 in the journal Virology.
“It is our hope that these existing drugs might ultimately help limit damage of fetal CMV infection, for which there is no treatment,” said Anthony van den Pol, professor of neurosurgery at Yale and senior author of the paper.
Survival rates and overall health of mice infected with CMV improved dramatically when the drugs were administered, the researchers report. Also, the virus was inhibited in human cells infected with CMV.
Congenital CMV is the major infectious cause of birth defects and neuro-developmental disabilities, including microcephaly, hearing loss, blindness, and mental retardation.
Sara Ornaghi is the lead author of the paper and primary funding for the research came from the National Institutes of Health.
If our reporting has informed or inspired you, please consider making a donation. Every contribution, no matter the size, empowers us to continue delivering accurate, engaging, and trustworthy science and medical news. Independent journalism requires time, effort, and resources—your support ensures we can keep uncovering the stories that matter most to you.
Join us in making knowledge accessible and impactful. Thank you for standing with us!